Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy

Investigating potential for an oral treatment in diabetic retinopathy First patient dosed in Phase 1b/2a clinical trialView original content:https://www.prnewswire.co.uk/news-releases/breye-therapeutics-commences-oral-dosing-of-danegaptide-in-patients-with-diabetic-retinopathy-302043736.html

en | boerse | 67921892 |